Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Immuno-oncology (IO) and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients. In IO and cell therapy clinical trial development, it is critical to identify the right dose level in early phase of trials thus improving the probability of success in confirmatory trials to test the superiority over other therapies. Given the complex mechanism interacting with immune system for IO drugs especially cell therapy, the traditional oncology dose finding trial designs may not serve the purpose.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Source Type: research